<br>        Inclusion Criteria:<br><br>          -  Community dwelling men and postmenopausal women who were ambulatory before sustaining<br>             a low-trauma, unilateral femoral neck fracture (displaced or nondisplaced)<br><br>          -  Other than femoral neck fracture, be free of incapacitating conditions and have a life<br>             expectancy of at least 2 years<br><br>          -  Have received or are eligible for treatment with internal fixation (sliding hip screw<br>             or multiple cancellous screws) for the femoral neck fracture (the surgical procedure<br>             itself is not performed as part of this study)<br><br>          -  Have given written informed consent (participant or proxy) after being informed of the<br>             risks, medications, and study procedures<br><br>        Exclusion Criteria:<br><br>          -  Increased baseline risk of osteosarcoma<br><br>          -  History of unresolved skeletal diseases affecting bone metabolism other than primary<br>             osteoporosis<br><br>          -  Abnormally elevated serum calcium at screening<br><br>          -  Abnormally elevated serum intact parathyroid hormone (PTH) (1-84) at screening<br><br>          -  Severe vitamin D deficiency at screening<br><br>          -  Active liver disease or jaundice<br><br>          -  Significantly impaired renal function<br><br>          -  Abnormal thyroid function not corrected by therapy<br><br>          -  History of malignant neoplasm in the 5 years prior to screening<br><br>          -  History of bone marrow or solid organ transplantation<br><br>          -  History of symptomatic nephrolithiasis or urolithiasis in the 1 year prior to<br>             screening<br><br>          -  Previous treatment with the following bone active drugs is allowed but must be<br>             discontinued at screening: oral bisphosphonates, selective estrogen receptor<br>             modulators (SERMs), calcitonin, estrogen (oral, transdermal, or injectable),<br>             progestin, estrogen analog, estrogen agonist, estrogen antagonist or tibolone, and<br>             active vitamin D3 analogs. Androgen or other anabolic steroid use must be<br>             discontinued, except for use of physiologic replacement testosterone<br><br>          -  Previous treatment with the following bone active drugs is exclusionary, if the stated<br>             treatment durations have been met: strontium ranelate for any duration, intravenous<br>             bisphosphonates in the 12 months preceding screening, and/or denosumab in the 6 months<br>             preceding screening<br><br>          -  Prior treatment with PTH, teriparatide, or other PTH analogs, or prior participation<br>             in any other clinical trial studying PTH, teriparatide, or other PTH analogs<br><br>          -  Local or systemic treatment with bone morphogenic proteins or any other growth factor<br><br>          -  Previous fracture(s) or bone surgery in the currently fractured hip<br><br>          -  Soft-tissue infection at the operation site<br><br>          -  Treatment with bone grafting or osteotomies<br><br>          -  Treatment with augmentation using any type of degradable cement, hydroxyapatite-coated<br>             implants, or with noninvasive interventions<br><br>          -  Associated major injuries of a lower extremity including fractures of the foot, ankle,<br>             tibia, fibula, knee, femur, femoral head, or pelvis; dislocations of the ankle, knee,<br>             or hip<br>      ;<br>        Inclusion Criteria:<br><br>          -  Community dwelling men and postmenopausal women who were ambulatory before sustaining<br>             a low-trauma, unilateral femoral neck fracture (displaced or nondisplaced)<br><br>          -  Other than femoral neck fracture, be free of incapacitating conditions and have a life<br>             expectancy of at least 2 years<br><br>          -  Have received or are eligible for treatment with internal fixation (sliding hip screw<br>             or multiple cancellous screws) for the femoral neck fracture (the surgical procedure<br>             itself is not performed as part of this study)<br><br>          -  Have given written informed consent (participant or proxy) after being informed of the<br>             risks, medications, and study procedures<br><br>        Exclusion Criteria:<br><br>          -  Increased baseline risk of osteosarcoma<br><br>          -  History of unresolved skeletal diseases affecting bone metabolism other than primary<br>             osteoporosis<br><br>          -  Abnormally elevated serum calcium at screening<br><br>          -  Abnormally elevated serum intact parathyroid hormone (PTH) (1-84) at screening<br><br>          -  Severe vitamin D deficiency at screening<br><br>          -  Active liver disease or jaundice<br><br>          -  Significantly impaired renal function<br><br>          -  Abnormal thyroid function not corrected by therapy<br><br>          -  History of malignant neoplasm in the 5 years prior to screening<br><br>          -  History of bone marrow or solid organ transplantation<br><br>          -  History of symptomatic nephrolithiasis or urolithiasis in the 1 year prior to<br>             screening<br><br>          -  Previous treatment with the following bone active drugs is allowed but must be<br>             discontinued at screening: oral bisphosphonates, selective estrogen receptor<br>             modulators (SERMs), calcitonin, estrogen (oral, transdermal, or injectable),<br>             progestin, estrogen analog, estrogen agonist, estrogen antagonist or tibolone, and<br>             active vitamin D3 analogs. Androgen or other anabolic steroid use must be<br>             discontinued, except for use of physiologic replacement testosterone<br><br>          -  Previous treatment with the following bone active drugs is exclusionary, if the stated<br>             treatment durations have been met: strontium ranelate for any duration, intravenous<br>             bisphosphonates in the 12 months preceding screening, and/or denosumab in the 6 months<br>             preceding screening<br><br>          -  Prior treatment with PTH, teriparatide, or other PTH analogs, or prior participation<br>             in any other clinical trial studying PTH, teriparatide, or other PTH analogs<br><br>          -  Local or systemic treatment with bone morphogenic proteins or any other growth factor<br><br>          -  Previous fracture(s) or bone surgery in the currently fractured hip<br><br>          -  Soft-tissue infection at the operation site<br><br>          -  Treatment with bone grafting or osteotomies<br><br>          -  Treatment with augmentation using any type of degradable cement, hydroxyapatite-coated<br>             implants, or with noninvasive interventions<br><br>          -  Associated major injuries of a lower extremity including fractures of the foot, ankle,<br>             tibia, fibula, knee, femur, femoral head, or pelvis; dislocations of the ankle, knee,<br>             or hip<br>      ;<br>        Inclusion Criteria:<br><br>          -  Community dwelling men and postmenopausal women who were ambulatory before sustaining<br>             a low-trauma, unilateral femoral neck fracture (displaced or nondisplaced)<br><br>          -  Other than femoral neck fracture, be free of incapacitating conditions and have a life<br>             expectancy of at least 2 years<br><br>          -  Have received or are eligible for treatment with internal fixation (sliding hip screw<br>             or multiple cancellous screws) for the femoral neck fracture (the surgical procedure<br>             itself is not performed as part of this study)<br><br>          -  Have given written informed consent (participant or proxy) after being informed of the<br>             risks, medications, and study procedures<br><br>        Exclusion Criteria:<br><br>          -  Increased baseline risk of osteosarcoma<br><br>          -  History of unresolved skeletal diseases affecting bone metabolism other than primary<br>             osteoporosis<br><br>          -  Abnormally elevated serum calcium at screening<br><br>          -  Abnormally elevated serum intact parathyroid hormone (PTH) (1-84) at screening<br><br>          -  Severe vitamin D deficiency at screening<br><br>          -  Active liver disease or jaundice<br><br>          -  Significantly impaired renal function<br><br>          -  Abnormal thyroid function not corrected by therapy<br><br>          -  History of malignant neoplasm in the 5 years prior to screening<br><br>          -  History of bone marrow or solid organ transplantation<br><br>          -  History of symptomatic nephrolithiasis or urolithiasis in the 1 year prior to<br>             screening<br><br>          -  Previous treatment with the following bone active drugs is allowed but must be<br>             discontinued at screening: oral bisphosphonates, selective estrogen receptor<br>             modulators (SERMs), calcitonin, estrogen (oral, transdermal, or injectable),<br>             progestin, estrogen analog, estrogen agonist, estrogen antagonist or tibolone, and<br>             active vitamin D3 analogs. Androgen or other anabolic steroid use must be<br>             discontinued, except for use of physiologic replacement testosterone<br><br>          -  Previous treatment with the following bone active drugs is exclusionary, if the stated<br>             treatment durations have been met: strontium ranelate for any duration, intravenous<br>             bisphosphonates in the 12 months preceding screening, and/or denosumab in the 6 months<br>             preceding screening<br><br>          -  Prior treatment with PTH, teriparatide, or other PTH analogs, or prior participation<br>             in any other clinical trial studying PTH, teriparatide, or other PTH analogs<br><br>          -  Local or systemic treatment with bone morphogenic proteins or any other growth factor<br><br>          -  Previous fracture(s) or bone surgery in the currently fractured hip<br><br>          -  Soft-tissue infection at the operation site<br><br>          -  Treatment with bone grafting or osteotomies<br><br>          -  Treatment with augmentation using any type of degradable cement, hydroxyapatite-coated<br>             implants, or with noninvasive interventions<br><br>          -  Associated major injuries of a lower extremity including fractures of the foot, ankle,<br>             tibia, fibula, knee, femur, femoral head, or pelvis; dislocations of the ankle, knee,<br>             or hip<br>      ;<br>        Inclusion Criteria:<br><br>          -  Community dwelling men and postmenopausal women who were ambulatory before sustaining<br>             a low-trauma, unilateral femoral neck fracture (displaced or nondisplaced)<br><br>          -  Other than femoral neck fracture, be free of incapacitating conditions and have a life<br>             expectancy of at least 2 years<br><br>          -  Have received or are eligible for treatment with internal fixation (sliding hip screw<br>             or multiple cancellous screws) for the femoral neck fracture (the surgical procedure<br>             itself is not performed as part of this study)<br><br>          -  Have given written informed consent (participant or proxy) after being informed of the<br>             risks, medications, and study procedures<br><br>        Exclusion Criteria:<br><br>          -  Increased baseline risk of osteosarcoma<br><br>          -  History of unresolved skeletal diseases affecting bone metabolism other than primary<br>             osteoporosis<br><br>          -  Abnormally elevated serum calcium at screening<br><br>          -  Abnormally elevated serum intact parathyroid hormone (PTH) (1-84) at screening<br><br>          -  Severe vitamin D deficiency at screening<br><br>          -  Active liver disease or jaundice<br><br>          -  Significantly impaired renal function<br><br>          -  Abnormal thyroid function not corrected by therapy<br><br>          -  History of malignant neoplasm in the 5 years prior to screening<br><br>          -  History of bone marrow or solid organ transplantation<br><br>          -  History of symptomatic nephrolithiasis or urolithiasis in the 1 year prior to<br>             screening<br><br>          -  Previous treatment with the following bone active drugs is allowed but must be<br>             discontinued at screening: oral bisphosphonates, selective estrogen receptor<br>             modulators (SERMs), calcitonin, estrogen (oral, transdermal, or injectable),<br>             progestin, estrogen analog, estrogen agonist, estrogen antagonist or tibolone, and<br>             active vitamin D3 analogs. Androgen or other anabolic steroid use must be<br>             discontinued, except for use of physiologic replacement testosterone<br><br>          -  Previous treatment with the following bone active drugs is exclusionary, if the stated<br>             treatment durations have been met: strontium ranelate for any duration, intravenous<br>             bisphosphonates in the 12 months preceding screening, and/or denosumab in the 6 months<br>             preceding screening<br><br>          -  Prior treatment with PTH, teriparatide, or other PTH analogs, or prior participation<br>             in any other clinical trial studying PTH, teriparatide, or other PTH analogs<br><br>          -  Local or systemic treatment with bone morphogenic proteins or any other growth factor<br><br>          -  Previous fracture(s) or bone surgery in the currently fractured hip<br><br>          -  Soft-tissue infection at the operation site<br><br>          -  Treatment with bone grafting or osteotomies<br><br>          -  Treatment with augmentation using any type of degradable cement, hydroxyapatite-coated<br>             implants, or with noninvasive interventions<br><br>          -  Associated major injuries of a lower extremity including fractures of the foot, ankle,<br>             tibia, fibula, knee, femur, femoral head, or pelvis; dislocations of the ankle, knee,<br>             or hip<br>